AU2008335855B2 - Seprase as a marker for cancer - Google Patents

Seprase as a marker for cancer Download PDF

Info

Publication number
AU2008335855B2
AU2008335855B2 AU2008335855A AU2008335855A AU2008335855B2 AU 2008335855 B2 AU2008335855 B2 AU 2008335855B2 AU 2008335855 A AU2008335855 A AU 2008335855A AU 2008335855 A AU2008335855 A AU 2008335855A AU 2008335855 B2 AU2008335855 B2 AU 2008335855B2
Authority
AU
Australia
Prior art keywords
cancer
seprase
marker
lung
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008335855A
Other languages
English (en)
Other versions
AU2008335855A1 (en
Inventor
Johann Karl
Jarema Peter Kochan
Markus Roessler
Wolfgang Rollinger
Michael Tacke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07023897A external-priority patent/EP2071337A1/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2008335855A1 publication Critical patent/AU2008335855A1/en
Application granted granted Critical
Publication of AU2008335855B2 publication Critical patent/AU2008335855B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57565—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen [CEA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
AU2008335855A 2007-12-10 2008-12-08 Seprase as a marker for cancer Ceased AU2008335855B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07023897.7 2007-12-10
EP07023897A EP2071337A1 (en) 2007-12-10 2007-12-10 Seprase as a marker for cancer
EP08015310 2008-08-29
EP08015310.9 2008-08-29
PCT/EP2008/010385 WO2009074275A1 (en) 2007-12-10 2008-12-08 Seprase as a marker for cancer

Publications (2)

Publication Number Publication Date
AU2008335855A1 AU2008335855A1 (en) 2009-06-18
AU2008335855B2 true AU2008335855B2 (en) 2012-08-30

Family

ID=40373548

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008335855A Ceased AU2008335855B2 (en) 2007-12-10 2008-12-08 Seprase as a marker for cancer

Country Status (14)

Country Link
US (1) US8980573B2 (https=)
EP (1) EP2223115B1 (https=)
JP (1) JP5563988B2 (https=)
KR (1) KR101202220B1 (https=)
CN (1) CN101896818B (https=)
AT (1) ATE524740T1 (https=)
AU (1) AU2008335855B2 (https=)
BR (1) BRPI0820793A2 (https=)
CA (1) CA2706115A1 (https=)
DK (1) DK2223115T3 (https=)
ES (1) ES2372442T3 (https=)
MX (1) MX2010004671A (https=)
PL (1) PL2223115T3 (https=)
WO (1) WO2009074275A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
EP2297581B1 (en) * 2008-07-03 2013-04-03 F. Hoffmann-La Roche AG Asc as a marker for lung cancer
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011213684B2 (en) 2010-02-05 2014-11-20 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012054732A2 (en) * 2010-10-20 2012-04-26 Rush University Medical Center Lung cancer tests
WO2012123299A1 (en) 2011-03-11 2012-09-20 Roche Diagnostics Gmbh Asc as marker for chronic obstructive pulmonary disease (copd)
WO2012123293A1 (en) * 2011-03-11 2012-09-20 Roche Diagnostics Gmbh Seprase as marker for chronic obstructive pulmonary disease (copd)
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
NZ703411A (en) 2012-06-27 2017-09-29 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
WO2014072465A1 (en) 2012-11-09 2014-05-15 Roche Diagnostics Gmbh In vitro capture and analysis of circulating tumor cells
WO2014085826A2 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
KR101619122B1 (ko) 2013-08-14 2016-05-10 연세대학교 산학협력단 탈메틸화 의존적 ａｓｃ 발현을 촉진시켜서 대장암 종양세포의 사멸감수성을 증진시키는 항암제 병용 투여용 후보물질의 스크리닝 방법
US10365281B2 (en) 2013-12-09 2019-07-30 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
PL230661B1 (pl) * 2014-01-29 2018-11-30 Centrum Onkologii Inst Im Marii Sklodowskiej Curie Oddzial W Gliwicach Metoda predykcyjna in vitro do przewidywania i/lub wykluczenia obecnosci raka pluc, zastosowanie in vitro metody predykcyjnej oraz zestaw testowy do wykrywania in vitro raka pluc
EP2916134B1 (en) * 2014-03-05 2017-08-16 Roche Diagnostics GmbH Use of Seprase for differential diagnosis of acute dyspnea
SG10202012249YA (en) 2014-12-08 2021-01-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
WO2016164815A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3029926C (en) * 2016-07-25 2023-01-03 Shizuoka Prefecture Diagnostic biomarker for extrahepatic bile duct cancer, intrahepatic bile duct cancer or gallbladder cancer
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
DE102017010455A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe
WO2019050275A1 (ko) * 2017-09-05 2019-03-14 (주)온코태그디아그노스틱 메티오닐 -티알엔에이 합성효소를 이용한 췌장암 진단 방법 및 이를 이용한 췌장암 진단 키트
WO2022007283A1 (zh) * 2020-07-08 2022-01-13 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
AU2004286307A1 (en) * 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
WO2007001420A2 (en) * 2004-10-22 2007-01-04 Genencor International, Inc. Isolating human antibodies
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
WO2007100374A2 (en) * 2005-12-19 2007-09-07 Trustees Of Tufts College Soft protease inhibitors and pro-soft forms thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IWASA, S. et al. Cancer Letters, 2005, v227, p229-236. *

Also Published As

Publication number Publication date
JP5563988B2 (ja) 2014-07-30
MX2010004671A (es) 2010-05-27
CA2706115A1 (en) 2009-06-18
EP2223115A1 (en) 2010-09-01
US20100240081A1 (en) 2010-09-23
PL2223115T3 (pl) 2012-02-29
KR101202220B1 (ko) 2012-11-16
AU2008335855A1 (en) 2009-06-18
WO2009074275A1 (en) 2009-06-18
CN101896818A (zh) 2010-11-24
ES2372442T3 (es) 2012-01-19
US8980573B2 (en) 2015-03-17
JP2011506941A (ja) 2011-03-03
KR20100091212A (ko) 2010-08-18
DK2223115T3 (da) 2011-12-12
CN101896818B (zh) 2016-01-20
ATE524740T1 (de) 2011-09-15
HK1150884A1 (zh) 2012-01-13
BRPI0820793A2 (pt) 2015-06-16
EP2223115B1 (en) 2011-09-14

Similar Documents

Publication Publication Date Title
AU2008335855B2 (en) Seprase as a marker for cancer
CA2760735C (en) Use of dppiv/seprase as a marker for cancer
EP2223116B1 (en) Marker panel for colorectal cancer
US10815517B2 (en) Use of DPPIV/seprase as a marker for cancer
US9518990B2 (en) Secernin-1 as a marker for cancer
EP2071337A1 (en) Seprase as a marker for cancer
US7785821B2 (en) Measurement of nicotinamde N-methyl transferase in diagnosis of lung cancer
US8951738B2 (en) CYBP as a marker for lung cancer
CA2586654C (en) Use of asc as a marker for colorectal cancer
HK1150884B (en) Seprase as a marker for cancer
HK1169168B (en) Use of dppiv/seprase as a marker for cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired